Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer

Gynecologic Oncology

Volumn 95, Issue 3, 2004, Pages 686-690

  Levy, Tally ^a,d   Inbar, Moshe ^b   Menczer, Joseph ^a   Grisaru, Dan ^b   Glezerman, Marek ^c   Safra, Tamar ^b  

^a Division of Gynecologic Oncology   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c WOLFSON MEDICAL CENTER   (Israel)

^d Wolfson Medical Center   (Israel)

Author keywords

Chemotherapy; Ovarian cancer; Primary peritoneal cancer; Topotecan

Indexed keywords

PLATINUM; TOPOTECAN;

ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG TOLERANCE; EVALUATION; FATIGUE; FEMALE; HEMATOLOGIC DISEASE; HUMAN; OVARY CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; RECURRENT DISEASE; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; EPITHELIAL CELLS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; TOPOTECAN;

EID: 9944233177     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.09.005     Document Type: Article

References (16)

1. R.T. Greenlee, M.B. Hill-Harmon, T. Murray, and M. Thum Cancer statistics, 2001 CA Cancer J. Clin. 1 2001 15 36
2. W.P. McGuire, W.J. Hoskins, M.F. Brady, P.R. Kucera, E.E. Partridge, and K.Y. Look Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N. Engl. J. Med. 334 1996 1 6
3. M.J. Piccart, K. Bertelsen, K. James, J. Cassidy, C. Mangioni, and E. Simonsen Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results J. Natl. Cancer Inst. 92 2000 699 708
4. W.P. McGuire, and R.F. Ozols Chemotherapy of advanced ovarian cancer Semin. Oncol. 25 1998 340 348
5. G.J. Creemers, G. Bolis, M. Gore, G. Scarfone, A.J. Lacave, and J.P. Guastalla Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study J. Clin. Oncol. 12 1996 3056 3061
6. W. ten Bokkel Huinink, M. Gore, J. Carmichael, A. Gordon, J. Malfetano, and I. Hudson Topotecan versus paclitaxel for the treatment of recurrent epithelial J. Clin. Oncol. 15 1997 2183 2193
7. A.P. Kudelka, D. Tresukosol, C.L. Edwards, R.S. Freedman, C. Levenback, and P. Chantarawiroj Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma J. Clin. Oncol. 14 1996 1552 1557
8. E.M. Swisher, D.G. Mutch, J.S. Rader, A. Elbendary, and T.J. Herzog Topotecan in platinum-and paclitaxel resistant ovarian cancer Gynecol. Oncol. 66 1997 480 486
9. P. Hoskins, E. Eisenhauer, S. Beare, M. Roy, P. Drouin, and G. Stuart Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study J. Clin. Oncol. 16 1998 2233 2237
10. M.A. Bookman, H. Malmstrom, G. Bolis, A. Gordon, A. Lissoni, and J.B. Krebs Topotecan for the treatment of advanced epithelial ovarian cancer: an open label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel J. Clin. Oncol. 16 1998 3345 3352
11. W.P. McGuire, J.A. Blessing, M.A. Bookman, S.S. Lentz, and C.J. Dunton Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group Study J. Clin. Oncol. 18 2000 1062 1067
12. H.D. Homesley, D.J. Hall, D.A. Martin, G.S. Lewandowski, L. Vaccarello, and W.A. Nahhas A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients Gynecol. Oncol. 83 2001 394 399
13. R.T. Morris, A. Munkarah, J. Field, V.V. Baker, R. Drake, and J. Malone Phase II trial of weekly topotecan in patients with potentially platinum sensitive relapsed ovarian and peritoneal cancer Proc. Am. Soc. Clin. Oncol. 21 2002 173 [abstract 2512]
14. R.T. Morris, R.D. Alvarez, S. Andrews, J. Malone, C. Bryant, and A. Munkarah Topotecan weekly bolus chemotherapy for potentially chemosensitive relapsed ovarian and peritoneal cancer-an update Proc. Am. Soc. Clin. Oncol. 22 2003 459 [abstract 1846]
15. G. Bolis, G. Scarfone, S. Tateo, G. Mangili, A. Villa, and F. Parazzini Response and toxicity to topotecan in sensitive ovarian cancer cases with small residual disease after first-line treatment with carboplatinum and paclitaxel Gynecol. Oncol. 80 2001 13 15
16. M. Gore, A. Oza, G. Rustin, J. Malfetano, H. Calvert, and D. Clarke-Pearson A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer Eur. J. Cancer 38 2002 57 63